Histotripsy Systems Market Size, Share & Industry Analysis By Product Type (Instruments and Accessories), By Technology Type (Cavitation-based Histotripsy and Boiling Histotripsy), By Application (Liver Tumors, Kidney Tumors, Pancreatic Tumors, and Others), By End User (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global histotripsy systems market size was valued at USD 63.8 million in 2025. The market is projected to grow from USD 95.7 million in 2026 to USD 592.5 million by 2034, exhibiting a CAGR of 25.6% during the forecast period.

Histotripsy systems are non-invasive, non-ionizing, and non-thermal medical devices that use focused ultrasound to liquefy and destroy targeted tumors at the cellular level mechanically. The growing prevalence of various types of cancer, rising hospital investments, and the rising demand for organ-preserving and non-invasive therapies are resulting in an increasing adoption rate of these products in the market. The rising geriatric population is further increasing the demand for surgical procedures among patients, thereby boosting the adoption rate of such systems in the market.

• For instance, according to the 2025 data published by the American Cancer Society (ACS), about 2.0 million new cancer cases are projected to occur in the U.S.

Furthermore, the growing integration of technological advancements in these devices among the major players, such as HistoSonics, among others, is further contributing to the demand for these devices in the market.

Download Free sample to learn more about this report.

Histotripsy Systems Market Trends

Strategic Investments and Partnerships to Fuel Market Demand

Strategic investments and partnerships are becoming prominent trends in the market. The companies are focusing on raising significant growth capital to strengthen their manufacturing capacity and further boost installations in healthcare settings. The companies are emphasizing clinical partnerships among academic institutes and hospitals to expand clinical applications globally.

Another emerging trend is the incorporation of real-time treatment monitoring and advanced imaging into histotripsy products. The integration of ultrasound visualization with accurate cavitation control improves procedural precision. Furthermore, healthcare professionals are increasingly focusing on image-guided systems that enable reproducible outcomes and streamlined workflow integration.

• In July 2025, HistoSonics collaborated with Proximie’s cloud-based operating system designed for intelligent ORs with an aim to strengthen the adoption rate for HistoSonics' Edison system.

Download Free sample to learn more about this report.

Market Dynamics

Market Drivers

Growing Prevalence of Cancer to Drive Market Growth

The increasing prevalence of chronic diseases, including various types of cancer such as liver cancer, lung cancer, and others, is resulting in the growing demand for localized and liver-preserving treatment modalities among the patient population, subsequently fueling the demand for histotripsy systems in the market.

• For instance, according to 2022 data published by the Centers for Disease Control & Prevention (CDC), it was reported that about 218,893 new lung cancers were reported in the U.S.

This, along with increasing capital investments and regulatory standardization, is further augmenting the adoption rate of these devices in the market. Therefore, the factors above, coupled with the growing emphasis of key players on introducing research and development activities to launch novel devices, are anticipated to fuel the adoption rate of these devices, thereby supporting the global market size.

Other Prominent Drivers

• Regulatory milestones including FDA De Novo clearance enabling commercial adoption.
• Positive early clinical outcomes and growing real-world treatment volumes.
• Investment and funding supporting commercialization, training and evidence generation.

Market Restraints

High Costs Associated with Histotripsy Procedures to Hinder Market Growth

The adoption of histotripsy products requires significant investment in infrastructure and workflow adaptation. The requirement of a dedicated procedural space, integration of imaging capabilities, and trained oncologic surgeons increases the cost of the entire setup, further supporting the procedural costs among patients.

Moreover, limited training programs are hampering the deployment rates. Additionally, the lack of standardization of treatment guidelines and clinical pathways for histotripsy products is another challenge that leads to limited penetration of these products in the market.

• For instance, according to the 2025 data published by the Agency for Care Effectiveness (ACE), the histotripsy procedure using Edison costs per patient are estimated to be between USD 9,527 and USD 17,500 at ambulatory surgical centers and hospital outpatient departments.

Market Opportunities

Expansion of Ambulatory Surgical Centers Presents a Lucrative Market Opportunity

The rapid shift from inpatient hospital procedures to ambulatory surgical centers (ASCs) and outpatient facilities presents a lucrative opportunity for the global market. The healthcare systems are increasingly focusing on patient convenience, cost-efficiency, and value-based care technologies that enhance outpatient workflows.

Furthermore, the prevalence of chronic conditions, the development of hospital infrastructure, and the rising number of outpatient clinics and ambulatory surgical centers are subsequently boosting the adoption of histotripsy systems in healthcare facilities. Additionally, improvement in reimbursement policies, among others, could further support the shift toward hospital outpatient departments and advanced ambulatory surgical centers, thereby contributing to the adoption rate for these products in the market.

• According to 2025 statistics published by Definitive Healthcare, there are about 10,000 active ambulatory surgical centers in the U.S.

Market Challenges

Limited Healthcare Access in Emerging Countries to Hinder Market Growth

The limited installed base and early commercial stage of histotripsy devices in emerging nations represent a market challenge for global market expansion. Histotripsy devices remain a highly advanced, capital-intensive technology that is currently limited to small academic and tertiary care centers, especially in emerging markets such as Brazil, Mexico, and others.

Moreover, in many emerging countries, adoption is limited by less developed healthcare infrastructure, reduced capital expenditure budgets, limited reimbursement policies, and others, thereby hampering the growth of the market.

• For instance, according to 2024 data published by The World Bank Group (WBG), it was reported that the combined government and donor spending on health averaged just USD 17.0 per capita in low-income countries, less than one-third of the USD 60.0 estimated minimum needed to deliver a basic package of essential services.

SEGMENTATION ANALYSIS

By Product Type

Increasing Prevalence of Cancer Led to Dominance of Instruments Segment

Based on the product type, the market is classified into instruments and accessories.

The instruments segment held the largest revenue share in 2025. The growth is owing to the growing prevalence of various types of cancer among patients, resulting in an increasing number of histotripsy procedures globally. This, along with the rising focus of prominent companies on R&D activities to launch novel products, is further anticipated to support the global histotripsy systems market growth.

• For instance, according to 2023 statistics published by Cancer Research U.K., around 375,400 people are diagnosed with cancer annually in the U.K.

The accessories segment is expected to grow at a CAGR of 23.3% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Technology Type

Increasing R&D Funding Led to Dominance of Cavitation-based Histotripsy Segment

Based on technology type, the market is bifurcated into cavitation-based histotripsy and boiling histotripsy.

The cavitation-based histotripsy segment dominated the global market in 2025 and accounted for 95.5% in 2025. The growth is due to the increasing number of histotripsy procedures, resulting in a rising research and development funding for cavitation-based histotripsy products, thereby contributing to the adoption rate of these products in the market.

• For instance, the Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has received Asia’s first Histotripsy 2.0 system as a donation from the Li Ka Shing Foundation (Foundation), which is serving patients in early 2025.

The segment of boiling histotripsy is set to flourish with a growth rate of 26.5% across the forecast period.

By Application

Growing Prevalence of Liver Cancer Led to Dominance of Liver Tumors Segment

Based on application, the market is segmented into liver tumors, kidney tumors, pancreatic tumors, and others.

The liver tumors segment dominated the global market in 2025. By application, the liver tumors segment accounted for 88.3% in 2025. The growth is due to the increasing prevalence of liver cancer, among others, resulting in a growing number of histotripsy procedures globally, thereby supporting the adoption rate of these products in the market.

• For instance, according to the statistics published by the World Cancer Research Fund, it was reported that about 866,136 new liver cancer cases were registered globally in 2022.

The segment of pancreatic tumors is set to flourish with a growth rate of 29.9% across the forecast period.

By End User

Increasing Number of Hospitals & ASCs Led to Segmental Dominance

Based on end user, the market is segmented into hospitals & ASCs, specialty clinics, and others.

The hospitals & ASCs segment dominated the market in 2025. The increasing healthcare expenditure, growing number of histotripsy procedures in hospitals, rising number of hospitals and ambulatory surgical centers, among others, are some of the key factors supporting the growth of the segment in the market. Furthermore, the segment is set to hold an 86.3% share in 2026.

• For instance, according to 2025 data published by Statistisches Bundesamt, there are about 1,874 hospitals in Germany.

In addition, specialty clinics’ end users are projected to grow at a 26.4% CAGR during the forecast period.

Histotripsy Systems Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market held the dominant share in 2024, valued at USD 35.6 million, and also took the leading share in 2025 with USD 50.4 million. The growing prevalence of chronic conditions, developed hospital infrastructure, and significant adoption of the Edison histotripsy system and novel histotripsy therapy platforms, growing FDA de novo approvals, among others, are some of the factors contributing to the growth of the segment in the market.

• For instance, according to 2022 statistics published by the World Cancer Research Fund (WCRF), about 43,492 cases were registered for liver cancer in the U.S.

U.S. Histotripsy Systems Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 60.8 million in 2026, accounting for roughly 63.5% of global sales.

Europe

Europe is projected to record a growth rate of 30.6% in the coming years, which is the second highest among all regions, and reach a valuation of USD 21.0 million by 2026. The growing adoption of technologically advanced histotripsy systems is mostly to support the market growth.

U.K. Histotripsy Systems Market

The U.K. market in 2026 is estimated at around USD 4.3 million, representing roughly 4.5% of global revenues.

Germany Histotripsy Systems Market

Germany’s market is projected to reach approximately USD 4.8 million in 2026, equivalent to around 5.1% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 5.7 million in 2026 and secure the position of the third-largest region in the market. The fastest growth in histotripsy procedures, expanding hospital expenditure, and improved healthcare access are anticipated to contribute to the development of the market. In the region, India and China are both estimated to reach USD 0.8 million and USD 1.6 million, respectively, in 2026.

Japan Histotripsy Systems Market

The Japan market in 2026 is estimated at around USD 1.6 million, accounting for roughly 1.7% of global revenues. Japan has historically reported a relatively increasing prevalence of various types of cancer, with a growing number of histotripsy procedures.

China Histotripsy Systems Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 1.6 million, representing roughly 1.6% of global sales.

India Histotripsy Systems Market

The India market size in 2026 is estimated at around USD 0.8 million, accounting for roughly 0.8% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 1.9 million in 2026.  The increase is owing to the development of healthcare infrastructure in these regions. The Middle East & Africa are also expected to grow primarily due to increasing improvement in reimbursement policies and improving healthcare access among the patient population. In the Middle East & Africa, the GCC is set to reach a value of USD 1.9 million in 2026.

South Africa Histotripsy Systems Market

The South Africa market is projected to reach around USD 0.4 million in 2026, representing roughly 0.5% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Research and Development Funding to Support Dominance of Companies Operating in Market

A significant focus on R&D activities, along with a substantial emphasis on strategic initiatives globally, is one of the crucial factors supporting the dominance of these companies in the market. HistoSonics was one of the major companies in the market in 2025. Moreover, the growing emphasis of key players on research and development funding is expected to strengthen their presence, which is supposedly to support the global histotripsy systems market share.

• For instance, in August 2025, HistoSonics announced a management-led majority stake acquisition by a group of globally recognized private and public investors, such as K5 Global, Bezos Expeditions, Wellington Management, and other new and existing investors. The transaction values HistoSonics at approximately USD 2.25 billion and accelerates the growth of the Edison System across new clinical indications and global markets.

Other key players, including the Regents of the University of Michigan and others, are also growing in the market, primarily due to their increasing focus on R&D activities to increase their brand presence in the market.

List of Key Histotripsy Systems Companies Profiled

• HistoSonics (U.S.)
• Focused Ultrasound Foundation (U.S.)
• Regents of the University of Michigan (U.S.)
• Mayo Foundation for Medical Education and Research (U.S.)
• Cleveland Clinic (U.S.)
• Johns Hopkins University (U.S.)
• University of Oxford (U.K.)
• Imperial College London (U.K.)

KEY INDUSTRY DEVELOPMENTS

• November 2025: Allina Health Cancer Institute care team at Abbott Northwestern Hospital has successfully performed the first histotripsy procedure in the Twin Cities, marking a significant milestone in noninvasive cancer treatment.
• June 2025: HistoSonics has announced the completion of enrollment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumors. This helped the company in strengthening its presence.
• August 2024: HistoSonics, announced the completion of an USD 102.0 million Series D financing. The round was led by Alpha Wave Ventures, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, and State of Wisconsin Investment Board, among others.
• February 2024: HistoSonics participated in the Innovative Devices Access Pathway (IDAP) Pilot Program, designed to fuel the development of cost-effective medical devices and their integration into the U.K. market.
• February 2024: The University of Chicago Medicine announced the treatment of patients with histotripsy, a new noninvasive technology that uses ultrasound energy to precisely destroy liver tumors.
• October 2023: HistoSonics received U.S. Food and Drug Administration (FDA) de novo clearance for HistoSonics Edison system to treat liver tumors.
• September 2022: HistoSonics announced the publication of results from their prospective Phase I clinical trial, named the THERESA Trial, conducted in Barcelona, Spain. The study reported results on eleven targeted tumors in the eight patients treated who all had unresectable end-stage multifocal liver tumors. Such results include colorectal liver metastases (CRLM) in 5 patients (7 tumors), breast cancer metastases in 1 (1 tumor), cholangiocarcinoma metastases in 1 (2 tumors), and hepatocellular carcinoma (HCC) in 1 (1 tumor).

REPORT COVERAGE

The report provides a detailed global histotripsy systems market analysis and focuses on key aspects such as leading companies and market segmentation, including product type, technology type, application, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation